Published in Vaccine Weekly, October 13th, 2004
Shares of the Concord-based drug developer closed at $2.47, up 36 cents or 17%, on the Nasdaq Stock Market. The stock set a 52-week high of $5.50 on April 21 and a year-low of $1.60 on July 23.
The vaccine has been shown in studies to prolong survival of tumor-bearing mice.
The studies were published in September 21, 2004,'s issue of Proceedings of the National Academy of Sciences.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly